-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
2022 Hebei Two Sessions | Representative Tian Pengmei: Improve Supporting Services to Further Boost the Pharmaceutical Industry
Category:
Time：2022-01-24
“Over the past year, guided by the goal of building a ‘Six Modernizations in Hebei,’ our province has continuously accelerated efforts to foster innovation-driven development and achieve leaps and bounds in progress. As a result, the pharmaceutical industry has significantly stepped up its pace to rank among the top players in China’s pharmaceutical sector,” said Tian Pengmei, a provincial People’s Congress deputy and Assistant President and General Manager of the Strategic Development Center at Shijiazhuang Fourth Pharmaceutical Co., Ltd. She added that favorable policies and a conducive business environment are driving the pharmaceutical industry to reach new heights. Our province’s biopharmaceutical sector is now experiencing a springtime of development. She expressed hope that in the future, supporting services will be further improved at an early date to continue boosting the pharmaceutical industry’s momentum.
“Over the past year, guided by the goal of building a ‘Six Modernizations in Hebei,’ our province has continuously accelerated efforts to foster innovation-driven development and achieve leaps and bounds in progress. As a result, the pharmaceutical industry has significantly stepped up its pace to rank among the top players in China’s pharmaceutical sector,” said Tian Pengmei, a provincial People’s Congress deputy and Assistant President and General Manager of the Strategic Development Center at Shijiazhuang Fourth Pharmaceutical Co., Ltd. She added that favorable policies and a conducive business environment are driving the pharmaceutical industry to reach new heights. Our province’s biopharmaceutical sector is now experiencing a springtime of development. She expressed hope that in the future, supporting services will be further improved at an early date to continue boosting the pharmaceutical industry’s momentum.
Representative Tian Pengmei said that favorable policies are empowering the pharmaceutical industry to achieve high-quality development. Last year, the provincial, municipal, and district governments successively introduced a series of policies aimed at supporting the development of the pharmaceutical industry and improving the business environment. These policies provided financial support throughout the entire lifecycle of enterprises—addressing such challenges as funding bottlenecks, scientific research and innovation, and talent incentives—thus enabling companies to accelerate the R&D and commercialization of new products. Last year, the companies were approved for 32 new products, four of which won bids in the national centralized drug procurement program, quickly entering the national market and generating over 800 million yuan in additional sales within just six months.
As a representative from the grassroots level, Tian Pengmei has firsthand experience of the improvements made to our province’s business environment. “The rapid development of enterprises is inseparable from the government’s precise and targeted services. Take Shijiazhuang as an example: the ‘Entrepreneurs-Mayor Symposium’ organized by the municipal government, as well as the ‘Secretary’s Direct Line’ and ‘Secretary’s Breakfast Meetings’ launched by the High-Tech Zone—these concrete initiatives aimed at connecting with and serving enterprises are all focused on addressing specific issues, thereby smoothing communication channels with industrial development and helping enterprises overcome many difficulties and concerns they face in their survival and growth.” Representative Tian Pengmei noted that pragmatic and efficient government services enable enterprises to concentrate more fully on their products and markets, on innovative R&D, and on high-quality development.
Speaking about promoting sustainable innovation and high-quality development of our province’s pharmaceutical industry, Representative Tian Pengmei believes that addressing the shortcomings in service-sector development and making services more attentive and tailored holds significant practical importance and far-reaching implications for enhancing our province’s capacity to attract investment, drive industrial growth, and foster industrial clusters. She suggests that, in response to the needs of industrial development, provincial-level branches for drug and medical device testing could be established in key pharmaceutical industry hubs within our province, such as Shijiazhuang High-tech Zone and Cangzhou Bohai New Area. This would provide stronger technical support for the development of our province’s biopharmaceutical industry and further boost industrial efficiency. At the same time, leveraging the government’s extensive network of connections with research institutes and other institutions, we should continue to deepen talent-service mechanisms, regularly assist enterprises in publishing information on domestic and international talent needs, and implement the “listing-and-command” initiative to help companies tackle challenges related to talent shortages and critical scientific research projects. By vigorously cultivating and strengthening leading enterprises and technology-driven companies in the industry, we can drive high-quality development of the entire province’s pharmaceutical sector.
Representative Tian Pengmei said that favorable policies are empowering the pharmaceutical industry to achieve high-quality development. Last year, the provincial, municipal, and district governments successively introduced a series of policies aimed at supporting the development of the pharmaceutical industry and improving the business environment. These policies provided financial support throughout the entire lifecycle of enterprises—addressing such challenges as funding bottlenecks, scientific research and innovation, and talent incentives—thus enabling companies to accelerate the R&D and commercialization of new products. Last year, the companies were approved for 32 new products, four of which won bids in the national centralized drug procurement program, quickly entering the national market and generating over 800 million yuan in additional sales within just six months.
As a representative from the grassroots level, Tian Pengmei has firsthand experience of the improvements made to our province’s business environment. “The rapid development of enterprises is inseparable from the government’s precise and targeted services. Take Shijiazhuang as an example: the ‘Entrepreneurs-Mayor Symposium’ organized by the municipal government, as well as the ‘Secretary’s Direct Line’ and ‘Secretary’s Breakfast Meetings’ launched by the High-Tech Zone—these concrete initiatives aimed at connecting with and serving enterprises are all focused on addressing specific issues, thereby smoothing communication channels with industrial development and helping enterprises overcome many difficulties and concerns they face in their survival and growth.” Representative Tian Pengmei noted that pragmatic and efficient government services enable enterprises to concentrate more fully on their products and markets, on innovative R&D, and on high-quality development.
Speaking about promoting sustainable innovation and high-quality development of our province’s pharmaceutical industry, Representative Tian Pengmei believes that addressing the shortcomings in service-sector development and making services more attentive and tailored holds significant practical importance and far-reaching implications for enhancing our province’s capacity to attract investment, drive industrial growth, and foster industrial clusters. She suggests that, in response to the needs of industrial development, provincial-level branches for drug and medical device testing could be established in key pharmaceutical industry hubs within our province, such as Shijiazhuang High-tech Zone and Cangzhou Bohai New Area. This would provide stronger technical support for the development of our province’s biopharmaceutical industry and further boost industrial efficiency. At the same time, leveraging the government’s extensive network of connections with research institutes and other institutions, we should continue to deepen talent-service mechanisms, regularly assist enterprises in publishing information on domestic and international talent needs, and implement the “listing-and-command” initiative to help companies tackle challenges related to talent shortages and critical scientific research projects. By vigorously cultivating and strengthening leading enterprises and technology-driven companies in the industry, we can drive high-quality development of the entire province’s pharmaceutical sector.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license